News | Antiplatelet and Anticoagulation Therapies | December 17, 2015

ROCKET AF Clinical Trial Executive Committee Releases Secondary Analysis

Findings reveal trial outcomes were not impacted by malfunctioning monitors recalled by FDA

ROCKET AF, executive committee, secondary analysis, rivaroxaban, FDA recall

December 17, 2015 — The ROCKET AF Clinical Trial Executive Committee announced its secondary analysis of the phase III trial (ROCKET AF) of the oral anticoagulant rivaroxaban. The analysis was prompted by a December 2014 U.S. Food and Drug Administration (FDA) recall of a device used in the study.

From 2006 to 2010, the ROCKET AF trial studied rivaroxaban as compared with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation and at increased risk for stroke. Following completion of the trial and rivaroxaban's initial FDA approval in 2011, the FDA issued a recall of the Alere INRatio and INRatio2 PT/INR Monitor system used in the trial to measure INR blood clotting levels for certain patient populations.

In order to understand the effect the possible malfunctioning of the device might have had in specific patient groups, the ROCKET AF Executive Committee and the Duke Clinical Research Institute conducted a secondary analysis of the trial findings.

The findings from the analysis are consistent with the results from the original trial and do not alter the conclusions of ROCKET AF—rivaroxaban is a reasonable alternative to warfarin and is non-inferior for the prevention of stroke and systemic embolism with less intracranial hemorrhage and fatal bleeding.

The ROCKET AF Executive Committee intends to publish a full description of this analysis and results as rapidly as possible.

This news may raise questions from patients who are currently prescribed rivaroxaban. It is important to recognize that there are risks with abruptly stopping any anticoagulant. Patients should discuss any questions with their physician.

For more information:

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Overlay Init